Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
Objective: To characterize its dose-response relationship, BI 655064 (an anti-CD40 monoclonal antibody) was tested as an add-on to mycophenolate and glucocorticoids in patients with active lupus nephritis (LN). Methods: A total of 121 patients were randomized (2:1:1:2) to receive placebo or BI 65506...
Saved in:
Main Author: | Jayne D.R. |
---|---|
Other Authors: | Mahidol University |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/88853 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Biomarkers for refractory lupus nephritis: A microarray study of kidney tissue
by: Thitima Benjachat, et al.
Published: (2018) -
Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue.
by: Pornpen Tantivitayakul, et al.
Published: (2015) -
A double-blind placebo-controlled study of an infusion of lexipafant (platelet-activating factor receptor antagonist) in patients with severe sepsis
by: Yupin Suputtamongkol, et al.
Published: (2018) -
Lupus Nephritis : current concepts
by: Yingyos Avihingsanon, et al.
Published: (2006) -
Pathogenic Mechanisms in the Development of Lupus Nephritis
by: ZHENG LING
Published: (2010)